A lthough myofibroblasts are believed to evolve from precursor cells, 1-4 recent studies using fate mapping technologies and engineered mouse models 5, 6 have demonstrated that endothelial cells (ECs) do not transdifferentiate into fibroblasts or myofibroblasts. Furthermore, whether the phenotypes of specific myofibroblast populations differ depending on the lineage of the cells from which they originated 7 and, by extension, whether these potential differences can impact the cells' role during myocardial recovery remains unclear.
A lthough myofibroblasts are believed to evolve from precursor cells, [1] [2] [3] [4] recent studies using fate mapping technologies and engineered mouse models 5, 6 have demonstrated that endothelial cells (ECs) do not transdifferentiate into fibroblasts or myofibroblasts. Furthermore, whether the phenotypes of specific myofibroblast populations differ depending on the lineage of the cells from which they originated 7 and, by extension, whether these potential differences can impact the cells' role during myocardial recovery remains unclear.
Human-induced pluripotent stem cells (hiPSCs) are exceptionally useful tools for studies in the life sciences 8 ; however, hiPSC-derived cells are less mature than their corresponding populations of adult somatic cells and, consequently, may be more likely to transdifferentiate into cells of unwanted lineages after transplantation. If so, this transdifferentiation could contribute to the limited benefits observed in studies of hiPSC-derived cardiac cell therapy. Here, we begin to address this question by characterizing the differentiation of myofibroblast-like cells from noncardiomyocyte cardiac cells (NMCCs; eg, ECs, smooth muscle cells [SMCs] , pericytes, and fibroblasts) that had been generated from hiPSCs in vitro and then evaluating the cellular activity and protein expression profiles of each hiPSC-NMCC-derived myofibroblast-like cell subpopulation. We also tested our hypothesis December 7, 2018 that the efficacy of cardiac cell therapy in infarcted mouse hearts could be improved by inhibiting the undesirable differentiation of hiPSC-NMCCs into myofibroblast-like cells and preserving the identity of the transplanted hiPSC-ECs, SMCs, pericytes, and fibroblasts.
Methods
The data that support the findings of this study are available from the first author on request.
A detailed description of the experimental procedures used in this investigation is provided in the Online Data Supplement.
Results

TGF-β Induces the Differentiation of hiPSCNMCCs Into Myofibroblast-Like Cells
hiPSCs were reprogramed from mature human cardiac fibroblasts, engineered to express GFP (green fluorescent protein) 9 and then differentiated into ECs, 10 SMCs, 11 fibroblasts, 12, 13 and pericytes 14 Figure 1A ; Online Figure I ) and by comparing the results to similar assessments in human umbilical vein ECs, human aortic SMCs, human dermal fibroblasts, and human brain vascular pericytes (Online Figure II) . Flow cytometry analyses of marker expression (ECs: CD31; SMCs: MYH11; fibroblasts: TE7; pericytes: NG2) indicated that each of the differentiated cell populations was >94% pure ( Figure 1B) , whereas functional assessments (ECs: tube formation and Dil-conjugated acetylated low-density lipoprotein uptake; SMCs: contractile response to carbachol and gel contraction assay; fibroblasts: wound healing and adhesion; pericytes: osteogenic differentiation and migration) What New Information Does This Article Contribute?
• hiPSC-NMCCs can differentiate into myofibroblast-like cells.
• Limiting the differentiation of transplanted hiPSC-NMCCs can improve their effectiveness for myocardial repair.
Here, we show that hiPSC-NMCCs differentiate into myofibroblastlike cells when cultured with TGF-β (transforming growth factor-β) or when transplanted into infarcted mouse hearts and that the phenotypes of the myofibroblast-like cells can differ depending on the lineage of origin. Our results also demonstrate that TGF-β inhibition significantly improved the efficacy of transplanted hiP-SC-NMCCs for cardiac repair, perhaps by limiting the unwanted differentiation of hiPSC-NMCCs into myofibroblast-like cells. Figure III) . The noncardiomyocyte cell populations were differentiated into myofibroblast-like cells by culturing them on Matrigel-coated plates with TGF-β1 (transforming growth factor-β1). [15] [16] [17] [18] Quantitative reverse transcription polymerase chain reaction analyses indicated that the mRNA levels of EC-, SMC-, fibroblast-, and pericyte-specific markers (PECAM1 [platelet and EC adhesion molecule 1] also known as CD31, MYH11, SHOX2, and NG2, respectively) declined during the 48-hour culture period, whereas mRNA levels of myofibroblast markers ( Figure 1C ). On completion of the myofibroblast differentiation protocol, immunofluorescence assessments confirmed that the cells were morphologically similar to myofibroblasts, as defined previously, 19 and expressed the myofibroblast marker proteins VMT, αSMA, Col1α1, and AOC3 (amine oxidase coppercontaining 3; Figure 1D ).
Activity and Protein Expression of hiPSC-EC, SMC, Pericyte, and Fibroblast-Myofibroblast-Like Cells Can Vary Depending on the hiPSC-NMCC Lineage
Assessments in cultured hiPSC-NMCC myofibroblast-like cells indicated that some cellular functions varied depending on the NMCC lineage. When evaluated via measurements of optical density, proliferation was significantly greater in hiPSC-SMC myofibroblast-like cells and pericyte myofibroblast-like cells than in hiPSC-EC myofibroblast-like cells and fibroblast myofibroblast-like cells (Figure 2A ), whereas were cultured for 16 h, and proliferation was calculated as the difference between optical density measurements (ΔOD) taken before and after the culture period. B, hiPSC-NMCC MFLCs were cultured for 12 h and stained for expression of Ki67 (bar=100 μm); (C) then, the percentage of Ki67-positive cells was quantified. D, hiPSC-NMCC MFLCs were cultured with 6 ng/mL IL-1 (interleukin-1) for 16 h, and then apoptosis was evaluated by measuring caspase 3 activity with a cell apoptosis kit. E, hiPSC-NMCC MFLCs (2×10 4 ) were seeded onto one surface of a gelatin-coated plate; 24 h later, the number of cells that had migrated to the other surface of the gelatin was determined and presented as a percentage of the total number of seeded cells. F, hiPSC-NMCC MFLCs ( 5×10 5 ) were cultured for 24 h in 12-well plates and lysed; then, the concentration of collagen I in the lysate was measured. One-way ANOVA followed by Tukey post hoc test for (A, D, E, and F); Kruskal-Wallis followed by Dunn post hoc test for (C). n=3 to 4 independent experiments. *P<0.05.
expression of the proliferation marker Ki67 was significantly greater in both hiPSC-SMC myofibroblast-like cells and pericyte myofibroblast-like cells than in hiPSC-EC myofibroblastlike cells, and in hiPSC-pericyte myofibroblast-like cells than in hiPSC-fibroblast myofibroblast-like cells (Figure 2B and 2C). Measurements of apoptosis (IL-1 [interleukin-1]-induced caspase 3 activity; Figure 2D ) were significantly higher, and of cell migration ( Figure 2E ) were significantly lower, in hiPSC-EC myofibroblast-like cells than in hiPSC-SMC, pericyte, and fibroblast myofibroblast-like cells, whereas collagen I production was lower in myofibroblast-like cells differentiated from hiPSC pericytes than in myofibroblast-like cells from the other 3 hiPSC-NMCC lineages ( Figure 2F ).
TGF-β (transforming growth factor-β) binds to serinethreonine kinase receptors at the cell surface, which activates the intracellular Smad/Snail signaling cascade, and TGF-β/ Smad3 signaling has been shown to promote collagen production 20 during fibrogenesis by activating mTOR (mammalian target of rapamycin). 21, 22 Thus, we investigated the mechanisms responsible for the TGF-β1-induced differentiation of hiPSC-NMCCs into myofibroblast-like cells by comparing Smad, Snail, and mTOR levels in differentiating hiPSC-EC, SMC, pericyte, and fibroblast myofibroblast-like cells. Western blot and quantitative reverse transcription polymerase chain reaction analyses indicated that TGF-β1 significantly increased Snail1 levels in differentiating hiPSC-EC, pericyte, and fibroblast myofibroblast-like cells (Online Figure IVA) , mTOR levels during hiPSC-EC, SMC, and pericyte myofibroblast-like cell differentiation (Online Figure IVB) , Smad3 levels during hiPSC-EC and hiPSC-SMC myofibroblast-like cell differentiation (Online Figure IVC) , and phosphorylated Smad3 levels during hiPSC-EC, SMC, pericyte, and fibroblast myofibroblast-like cell differentiation (Online Figure IVD) but not in the presence of an anti-TGF-β antibody or galunisertib, which inhibits the TGF-β receptor (Online Figure IV) .
Protein expression in hiPSC-EC, SMC, pericyte, and fibroblast-myofibroblast-like cells was evaluated via isobaric tagging for relative and absolute quantification liquid chromatography tandem-mass spectrometry/mass spectrometry. Quantifiable data suitable for statistical analysis (n, ≥2) were available for 2296 proteins, and the expression of a number of proteins involved in fibrosis and cellular remodeling (Online Figure VA) , proliferation (Online Figure VB) , and apoptosis (Online Figure VC) varied significantly across the 4 hiPSC-NMCC lineage myofibroblast-like cell populations. Thus, the activity and protein expression of TGF-β-induced hiPSC-EC, SMC, pericyte, and fibroblast-myofibroblast-like cells may vary somewhat depending on the lineage of the hiPSC-NMCCs.
Pathways Involved in Integrin Signaling, Endocytosis, and Remodeling Are Activated in hiPSC-EC, SMC, Pericyte, and FibroblastMyofibroblast-Like Cells
A total of 701 proteins were expressed at significantly higher or lower levels in hiPSC-NMCC myofibroblast-like cells than in the hiPSC-NMCCs from which they were differentiated (Online Table I ). When evaluated with Ingenuity Pathway Analysis software (Online Figure VI) , the most significant differences were observed for pathways involved in integrin, actin-cytoskeletal, and agrin signaling (remodeling), which is consistent with the roles of myofibroblasts in fibrosis and injury repair. The most significantly different cellular functions were growth and proliferation, death and survival, and movement, which are consistent with the results from our in vitro functional analyses, and the top disease/disorder categories were organismal injury and abnormalities, infectious response, and cancer (Online Table II) . Notably, actin-cytoskeletal signaling and agrin signaling seemed to be more and less strongly associated, respectively, with hiPSC-EC myofibroblast-like cells than with the other hiPSC-NMCC myofibroblast-like cell lineages.
Protein Secretion by hiPSC-EC, SMC, Pericyte, and Fibroblast-Myofibroblast-Like Cells Is Partially Dependent on the hiPSC-NMCC Lineage
Proteins secreted into the medium of cultured hiPSC-NMCC myofibroblast-like cells were collected and evaluated via orbitrap mass spectrometry (Online Table III ) and ELISA. Both TGF-β1 ( Figure 3A ) and IL-1 ( Figure 3B ) levels were significantly greater in hiPSC-SMC myofibroblast-like cell medium than in medium from the other 3 hiPSC-NMCC myofibroblast-like cells, whereas IL-1 levels were significantly higher in hiPSC-pericyte myofibroblast-like cell medium than in hiPSC-fibroblast myofibroblast-like cell medium and in hiPSC-EC myofibroblast-like cell medium than in either hiPSC-pericyte or fibroblast myofibroblast-like cell medium. Furthermore, the medium from hiPSC-SMC myofibroblast-like cells induced hiPSC-ECs, SMCs, pericytes, and fibroblasts to express Col1α1, VMT, and αSMA but not in the presence of the anti-TGF-β antibody or galunisertib, and even higher expression levels were achieved when the cells were treated with TGF-β1 ( Figure 3C and 3D) . Conditioned medium from ≥1 lineages of hiPSC-NMCC myofibroblast-like cells also promoted the expression of cTnI (cardiac troponin I; Figure 3E ) and Con43 (connexin 43; Figure 3F ) in cultured hiPSC-derived cardiomyocytes, enhanced both migration and cytokine expression (eg, IL-1 and VEGF [vascular endothelial growth factor]) in macrophages (Online Figure VII) , and stimulated the production of Col1α1, VMT, and αSMA in hiPSC-NMCCs (Online Figure VIII) . Collectively, these results suggest that factors secreted by the hiPSC-NMCC myofibroblast-like cells promoted the growth and maturation of cardiomyocytes, the inflammatory response in macrophages, and other reparative functions in hiPSC-NMCCs.
hiPSC-NMCCs Can Differentiate Into Myofibroblast-Like Cells After Transplantation Into Infarcted Mouse Hearts
Because the hiPSC-derived ECs, SMCs, pericytes, and fibroblasts readily differentiated into myofibroblast-like cells after treatment with TGF-β1 in vitro, we investigated whether they also differentiate into myofibroblast-like cells after transplantation into infarcted mouse hearts. Myocardial infarction (MI) was surgically induced by ligating the left anterior descending coronary artery; then, animals in the MI+EC group, the MI+SMC group, the MI+PC group, and the MI+FB group were treated with hiPSC-ECs, SMCs, pericytes, and fibroblasts, respectively, and animals in the MI+EC+G, Figure 3 . Conditioned medium from cultured human-induced pluripotent stem cell (hiPSC) smooth muscle cell (SMC) myofibroblast-like cells (MFLCs) alters protein expression in cultured hiPSC noncardiomyocyte cardiac cells (NMCCs) and cardiomyocytes. A and B, The media of cultured hiPSC-endothelial cell (EC), SMC, pericyte (PC), and fibroblast (FB) MFLCs was collected, and (A) TGF-β1 (transforming growth factor-β1) and (B) IL-1 (interleukin-1) levels were evaluated via ELISA. C and D, A combined population of hiPSC-ECs, SMCs, pericytes, and fibroblasts was cultured with TGF-β1, with an anti-TGF-β antibody (Ab), with the TGF-β receptor 1 blocker galunisertib (G), with conditioned medium from hiPSC-SMC MFLCs (CM), with CM and an anti-TGF-β antibody (CM+Ab), with CM and galunisertib (CM+G), or under standard conditions (Con); then, Col1α1 (type I collagen α1), VMT (vimentin), and αSMA (α-smooth muscle actin; C) mRNA and (D) protein levels in the medium from the cultured cells were evaluated via quantitative reverse transcription polymerase chain reaction and Western blot, respectively. E and F, hiPSC-derived cardiomyocytes were cultured with CM from hiPSC-SMC MFLCs or under standard conditions; then, (E) cTnI (cardiac troponin I) and (F) Con43 (connexin 43) expression were evaluated via (Ei and Fi) immunofluorescence and (Eii and Fii) Western blot. Nuclei were counterstained with DAPI, and Western blots of β-actin or GAPDH levels were evaluated to confirm equal loading (bar=100 μm). One-way ANOVA followed by Tukey post hoc test for (A-C); 2-tailed Student t test for (E and F). n=3 to 4 independent experiments. *P<0.05, **P<0.01 vs control, CM+AB and CM+G.
MI+SMC+G, MI+PC+G, and MI+FB+G groups were treated with the indicated hiPSC-NMCCs and the TGF-β receptor 1 inhibitor galunisertib. The cells (3×10 5 per mouse) were injected 15 minutes after MI induction into 3 sites of the heart (1×10 5 cells per injection site); 1 site was located in the infarcted region, and 2 were located in the region surrounding the infarct. Galunisertib (75 mg/kg per day) was administered orally from the day of MI induction through day 7 after MI, when the animals were euthanized.
Sections from animals in the MI+EC and MI+EC+G groups were stained for expression of the hCD31 (human CD31 variant) to identify hiPSC-ECs that had retained their EC lineage and for the coexpression of hVMT (human VMT) and αSMA to identify hiPSC-ECs that had differentiated into myofibroblast-like cells ( Figure 4A and 4B) . Similarly, hiPSC-SMCs that had retained their SMC lineage after transplantation were identified by the coexpression of hCalp1 (human calponin 1) and MYH11 or by hCalp1 expression in the absence of hVMT expression ( Figure 4A and 4C), whereas hiPSC pericytes ( Figure 4A and 4D) and hiPSC fibroblasts ( Figure 4A and 4E) that had retained their lineages were identified by the expression of hNG2 (human NG2) and hTE7 (human TE7), respectively; cells that had differentiated into myofibroblast-like cells were identified via the coexpression of hVMT and αSMA. The proportion of hiPSC-NMCCs that differentiated into myofibroblast-like cells ranged from ≈21% to ≈35% in the MI+EC, MI+SMC, MI+PC, and MI+FB groups ( Figure 4F) ; however, <7% of the transplanted cells differentiated into myofibroblastlike cells in the groups that were administered galunisertib ( Figure 4B through 4F) . Evidence of the differentiation of hiPSC-NMCCs into myofibroblast-like cells was also observed in swine hearts: the animals were injected with GFPlabeled hiPSC-SMCs and hiPSC-ECs after experimentally induced MI, and a number of the cells in sections collected 4 weeks after treatment coexpressed hVMT and αSMA or hCalp1 and VMT (Online Figure IX) . Thus, a substantial proportion of hiPSC-NMCCs differentiated into myofibroblast-like cells after transplantation into infarcted hearts, but this conversion appeared to be attenuated via the blockade of TGF-β activity.
TGF-β Inhibition Limits the Differentiation of hiPSC-NMCCs Into Myofibroblast-Like Cells In Vivo and Improves the Potency of Transplanted hiPSC-NMCCs for Myocardial Recovery
One of the primary goals of hiPSC-NMCC transplantation after MI is to limit the size of the infarct by providing cellular components that can contribute directly to angiogenesis and other processes involved in myocardial repair. Thus, the differentiation of transplanted hiPSC-NMCCs into myofibroblast-like cells likely limits the cells' therapeutic potency. Furthermore, although TGF-β inhibition during the early stage of recovery from MI has been associated with increases in mortality and left ventricular remodeling, 23, 24 inhibition during the later stages seems to reduce fibrosis, 25 so we investigated whether combining hiPSC-NMCC transplantation with galunisertib administration at week 1 after MI would improve measures of cardiac function, fibrosis, hypertrophy, and vessel density. Experiments were conducted in mice that had been treated with hiPSC-NMCCs (0.75×10 5 of each of the 4 cell types) and galunisertib both alone (ie, the MI+cells and MI+Gal groups, respectively) and in combination (the MI+cells+Gal group), or neither experimental treatment (ie, the MI group); the dose of galunisertib was chosen to be sufficient for inhibiting hiPSC-NMCCs myofibroblast-like cell differentiation. A fifth group of animals underwent all surgical procedures for MI induction except coronary artery ligation and recovered without either experimental treatment (the Sham group).
Echocardiographic assessments ( Figure 5A ) of left ventricular ejection fraction ( Figure 5B ) and fractional shortening ( Figure 5C ) were significantly greater in the MI+cells group than in MI animals and in the MI+Cells+Gal group than in either MI+cells or MI animals, at week 4. Furthermore, measurements of fibrotic area ( Figure 5D and 5E), heart weight/bodyweight ratio ( Figure 5F ), total vascular density ( Figure 5G and 5H), and arteriole density ( Figure 5G and 5I) were significantly better after treatment with both hiPSCNMCCs and galunisertib than after treatment with hiPSCNMCCs alone, and in the MI+cells group than in MI animals, whereas fibrotic areas and heart weight/bodyweight ratios, but no other measured parameter, were significantly better in the MI+Gal group than in the MI group. Notably, the engraftment rate in MI+cells and MI+cells+Gal animals was similar (Online Figure X) , indicating that the difference in recovery cannot be attributed to a TGF-β-induced improvement in engraftment. Thus, the effectiveness of transplanted hiPSC-ECs, SMCs, pericytes, and fibroblasts for treatment of MI in mice appeared to improve when a TGF-β receptor inhibitor was used to prevent the transplanted cells from differentiating into myofibroblast-like cells.
Discussion
During the last 2 decades, numerous preclinical studies have reported that the functional benefits of cardiac cell therapy are mediocre and accompanied by an extremely low rate of cell engraftment. Here, we investigated whether the limited potency of hiPSC-derived cells for cardiac repair may be at least partially attributable to their transdifferentiation into myofibroblast-like cells after transplantation. The primary findings of our current investigation were that (1) hiPSC-derived NMCCs (hiPSC-ECs, SMCs, pericytes, and fibroblasts) transdifferentiate into myofibroblast-like cells when exposed to TGF-β in culture and when transplanted into infarcted mouse hearts, and (2) inhibiting hiPSC-NMCC myofibroblast-like cell transdifferentiation via oral administration of the TGF-β receptor inhibitor galunisertib improves the therapeutic potency of transplanted hiPSC-NMCCs for myocardial repair by attenuating the unwanted transdifferentiation of hiPSCderived cells.
In response to myocardial injury, myofibroblasts regulate and contribute to the synthesis and secretion of ECM (extracellular matrix) components (collagens, fibronectin, and laminin), as well as the production of proteins and MMPs (metalloproteinases) that are involved in fibrosis, 26, 27 which, some evidence suggests, 28 may be a direct response to the TGF-β contributes to tumor growth, inflammatory fibrosis, and tissue repair by promoting cell growth and differentiation, inducing the epithelial-to-mesenchymal transition, modulating angiogenesis and stromal ECM production, and regulating immune surveillance. 31 Thus, galunisertib, which inhibits TGF-β receptor 1, has been evaluated as a treatment for cancer, as well as fibrosis of the liver, lung, and other organs 32, 33 and has been shown to reduce fibroblast proliferation, the production of fibrotic ECM proteins, 34 and immune cell infiltration. 35 TGF-β also has a role in MI, cardiac remodeling, and fibrosis, 23, 36 but the effect of TGF-β inhibition on myocardial function after MI is debatable and seems to be time dependent. During the early stage of recovery, TGF-β inhibition has been associated with declines in cardiac function, increases in mortality, and the exacerbation of left ventricular remodeling, 24 whereas inhibition during later stages seems to reduce fibrosis. 25 In the present study, TGF-β inhibition with galunisertib effectively improved the efficacy of cell therapy, likely by decreasing the unwanted differentiation of the transplanted hiPSC-NMCCs.
The results from these earlier studies are consistent with those in our current report, because the improvements in measures of cardiac function, remodeling, fibrotic area, and vascularity achieved by adding galunisertib to hiPSC-NMCC therapy were observed in animals treated 1 week (rather than a few minutes) after MI induction. Furthermore, although the low dose of galunisertib used here was sufficient to prevent the unwanted transdifferentiation of transplanted hiPSC-NMCCs, it was not associated with any obvious side effects during the 3 weeks of this study. However, the broad and complex role of TGF-β signaling in the infarcted heart is difficult to evaluate in experiments with hiPSCs, because TGF-β is required for maintaining the pluripotency of human stem cells 37, 38 and, consequently, cannot be knocked out of hiPSCs before the cells are differentiated, while pharmacological agents used to inhibit TGF-β signaling can have off-target effects. Thus, a more thorough investigation of the involvement of TGF-β signaling in differentiating hiPSC-NMCCs and in the regenerative potency of hiPSC-derived cells is warranted with hiPSCs carrying a conditional TGF-β knockout mutation.
Although the results from our study convincingly demonstrate that hiPSC-NMCCs can transdifferentiate into myofibroblast-like cells when treated with TGF-β in vitro or after transplantation into infarcted mouse hearts, we have not shown that endogenous cardiac cells undergo changes in cell identity after MI, and our experiments do not address whether the differentiation of hiPSC-NMCCs into myofibroblast-like cells contributes to pathological fibrosis.
Conclusions
The results presented here demonstrate that hiPSC-derived ECs, SMCs, pericytes, and fibroblasts transdifferentiated into myofibroblast-like cells when cultured with TGF-β or when transplanted into infarcted mouse hearts. Furthermore, the differentiation of transplanted hiPSC-NMCCs into myofibroblast-like cells was attenuated by inhibiting TGF-β signaling, and measurements of infarct size and cardiac function in a murine MI model were significantly better in animals treated with both hiPSC-NMCCs and a TGF-β inhibitor than with hiPSC-NMCCs alone. Figure 5 Continued. G-I, Sections from the border zone of ischemia in the hearts were (G) immunofluorescently stained for the presence of CD (cluster of differentiation) 31 and αSMA (α-smooth muscle actin), and nuclei were counterstained with DAPI (bar=100 μm); then, (H) vascular density was determined by quantifying the expression of CD31, and (I) arteriole density was determined by quantifying the coexpression of CD31 and αSMA. Data displayed in panels (D-I) were obtained from animals sacrificed 4 wk after MI. One-way ANOVA followed by Tukey post hoc test for (B, C, E, F, H, and I). n=8 to 10 mice per group, 6 sections per mouse. *P<0.05, **P<0.01.
